STOCK TITAN
  1. Home
  2. Sec-filings
  3. APRE
  4. [EFFECT] Aprea Therapeutics, Inc. SEC Filing

[EFFECT] Aprea Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 19, 2026 5:00 P.M.
Form: S-3
CIK: 0001781983
Company Name: Aprea Therapeutics, Inc.
File Number: 333-293609

Source: View Original Filing on SEC EDGAR

Aprea Therapeutics, Inc.

NASDAQ:APRE

View APRE Stock Overview →

APRE Rankings

#6465 Ranked by Market Cap
N/A Ranked by Dividends

APRE Latest News

Mar 16, 2026
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Feb 18, 2026
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Feb 17, 2026
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 12, 2026
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
Feb 4, 2026
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

APRE Latest SEC Filings

Mar 19, 2026
[424B3] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Mar 17, 2026
[S-3/A] Aprea Therapeutics, Inc. Amended Shelf Registration Statement
Mar 16, 2026
[Form 4] Aprea Therapeutics, Inc. Insider Trading Activity
Mar 16, 2026
[Form 4] Aprea Therapeutics, Inc. Insider Trading Activity
Mar 16, 2026
[10-K] Aprea Therapeutics, Inc. Files Annual Report

APRE Stock Data

8.74M
5.32M
Biotechnology
Pharmaceutical Preparations
Link
United States
DOYLESTOWN